Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0SQFKC
ADC Name
anti-TRBC1-SG3249
Synonyms
ADC
   Click to Show/Hide
Organization
THE JOHNS HOPKINS UNIVERSITY[US/US]
Drug Status
Investigative
Drug-to-Antibody Ratio
2.6
Structure
Antibody Name
undisclosed
Antigen Name
T cell receptor beta-chain constant region 1 (TRBC1)
  Antigen Info 
Payload Name
SG3199
  Payload Info 
Therapeutic Target
Human Deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
CL2A
  Linker Info 
Conjugate Type
Random conjugation through nucleophilic lysines
Combination Type
SG3249
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 8 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
0.006
nM
CVCL_1126
Chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
Half Maximal inhibitory Concentration (lC50) 
0.009
nM
CVCL_1820
Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia
Half Maximal inhibitory Concentration (lC50) 
0.012
nM
CVCL_1714
Childhood T lymphoblastic lymphoma, T-cell non-Hodgkin lymphoma
Half Maximal inhibitory Concentration (lC50) 
0.014
nM
CVCL_0065
Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia
Half Maximal inhibitory Concentration (lC50) 
0.016
nM
CVCL_1240
Sezary syndrome
Half Maximal inhibitory Concentration (lC50) 
0.016
nM
CVCL_1820
Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia
Half Maximal inhibitory Concentration (lC50) 
0.025
nM
CVCL_0065
Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia
Half Maximal inhibitory Concentration (lC50) 
0.03
nM
CVCL_0065
Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 8 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.006 nM
Method Description
IC50 Values (nM) of anti-TRBC1-SG3199 in T-cell cancer cell lines in CML-T1 TRBC1
In Vitro Model Chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia CML-T1 TRBC1 cells CVCL_1126
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.009 nM
Method Description
IC50 Values (nM) of anti-TRBC1-SG3199 in T-cell cancer cell lines in HPB-ALL TRBC2
In Vitro Model Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia HPB-ALL TRBC2 cells CVCL_1820
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.012 nM
Method Description
IC50 Values (nM) of anti-TRBC1-SG3199 in T-cell cancer cell lines in SUP-T1 TRBC1
In Vitro Model Childhood T lymphoblastic lymphoma, T-cell non-Hodgkin lymphoma SUP-T1 TRBC1 cells CVCL_1714
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.014 nM
Method Description
IC50 Values (nM) of anti-TRBC1-SG3199 in T-cell cancer cell lines in Jurkat TCR-KO
In Vitro Model Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia Jurkat TCR-KO cells CVCL_0065
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.016 nM
Method Description
IC50 Values (nM) of anti-TRBC1-SG3199 in T-cell cancer cell lines in H9 TRBC1
In Vitro Model Sezary syndrome H9 TRBC1 cells CVCL_1240
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.016 nM
Method Description
IC50 Values (nM) of anti-TRBC1-SG3199 in T-cell cancer cell lines in HPB-ALL TRBC1
In Vitro Model Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia HPB-ALL TRBC1 cells CVCL_1820
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.025 nM
Method Description
IC50 Values (nM) of anti-TRBC1-SG3199 in T-cell cancer cell lines in Jurkat TRBC1
In Vitro Model Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia Jurkat TRBC1 cells CVCL_0065
Experiment 8 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.03 nM
Method Description
IC50 Values (nM) of anti-TRBC1-SG3199 in T-cell cancer cell lines in Jurkat TRBC2
In Vitro Model Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia Jurkat TRBC2 cells CVCL_0065
References
Ref 1 TRBC targeting antibody-drug conjugates